Chest
Volume 107, Issue 3, March 1995, Page 883
Journal home page for Chest

Communications to the Editor
Allergic Bronchopulmonary Aspergillosis Treated With Itraconazole

https://doi.org/10.1378/chest.107.3.883Get rights and content

Section snippets

To the Editor

The study reported by Drs. Mroueh and Spock1 in the January 1994 issue of Chest emphasizes the efficacy of corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA), an unusual complication of cystic fibrosis. But patients who failed to respond could be treated with itraconazole, an orally administered triazole antifungal agent.

Mannes et al2 recently reported favorable results with itraconazole as adjunctive therapy for ABPA in twins with cystic fibrosis. Using the same drug,

References (5)

There are more references available in the full text version of this article.

Cited by (48)

  • Allergic bronchopulmonary aspergillosis

    2009, Chest
    Citation Excerpt :

    We use inhaled corticosteroids only for the control of asthma once the oral prednisolone dose is reduced to < 10 mg/day. Ketoconazole has been tried in the past147 and has been replaced by the less toxic agent, itraconazole.130,141,148–160 Only two randomized controlled studies (84 patients) have evaluated the role of itraconazole in ABPA.130,156

  • Allergic bronchopulmonary aspergillosis

    2002, Revue Francaise d'Allergologie et d'Immunologie Clinique
  • Antifongiques et aspergilloses

    2001, Revue Francaise des Laboratoires
View all citing articles on Scopus

Communications for this section will be published as space and priorities permit. The comments should not exceed 350 words in length, with a maximum of five references; one figure or table can be printed. Exceptions may occur under particular circumstances. Contributions may include comments on articles published in this periodical, or they may be reports of unique educational character. Specific permission to publish should be cited in a covering letter or appended as a postscript.

View full text